Startseite IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective

  • Rajmohan Seetharaman ORCID logo , Rhea Monteiro , Jay Maradia ORCID logo EMAIL logo und Raakhi Tripathi
Veröffentlicht/Copyright: 11. Juni 2024
Journal of Basic and Clinical Physiology and Pharmacology
Aus der Zeitschrift Journal of Basic and Clinical Physiology and Pharmacology Band 35 Heft 4-5

Abstract

IcoSema, a groundbreaking approach to diabetes management, combines insulin icodec and semaglutide to offer a transformative treatment option. Insulin icodec delivers consistent glucose-lowering effects with once-weekly dosing, while semaglutide, a GLP-1 agonist, stimulates insulin secretion and aids in weight loss. This comprehensive article evaluates the potential of IcoSema from a clinical pharmacology perspective, examining the pharmacokinetics, efficacy, safety, compliance and cost-effectiveness of its individual components, as well as considering comparable combination therapies like iGlarLixi and IDegLira. By analysing these crucial factors, the article aims to determine the potential of IcoSema in the field of diabetes management. The combination of insulin icodec and semaglutide has the potential to provide improved glycaemic control, weight management, and simplified treatment regimens, addressing common challenges faced in diabetes management. Safety, compliance and cost considerations are important aspects of evaluating this combination therapy. Ongoing trials investigating IcoSema are expected to provide valuable insights into its efficacy, safety and comparative effectiveness. By addressing concerns such as potential side effects, individual patient response and drug interactions, healthcare providers can optimize treatment outcomes and enhance the management of type 2 diabetes.

Keywords: insulin icodec; semaglutide; pharmacokinetics; efficacy; safety; cost effectiveness
Corresponding author: Dr. Jay Maradia, Junior Resident, Department of Pharmacology and Therapeutics, Seth G.S. Medical College and KEM Hospital, Parel, Mumbai, 400012, India, E-mail:

  1. Research ethics: Not applicable.

  2. Informed consent: Not applicable.

  3. Author contributions: All four authors contributed in; 1. Conception and interpretation of data for the work. 2. Drafting and revising content. 3. Final approval of the version. 4. Accountability for all aspect of the work.

  4. Competing interests: The authors state no conflict of interest.

  5. Research funding: None declared.

  6. Data availability: Data sharing is not applicable to this article as no data datasets were generated or analyzed during the current study.

References

1. Najafipour, H, Farjami, M, Sanjari, M, Amirzadeh, R, Shadkam Farokhi, M, Mirzazadeh, A. Prevalence and incidence rate of diabetes, pre-diabetes, uncontrolled diabetes, and their predictors in the adult population in southeastern Iran: findings from KERCADR study. Front Public Health 2021;9:611652. https://doi.org/10.3389/fpubh.2021.611652.Suche in Google Scholar PubMed PubMed Central

2. Committee ADAPP. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022. Diabetes Care 2022;45:S125–43. https://doi.org/10.2337/dc22-s009.Suche in Google Scholar PubMed

3. A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to weekly insulin icodec - full text view - ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT05352815 [cited 2023 Jul 7].Suche in Google Scholar

4. Nishimura, E, Pridal, L, Glendorf, T, Hansen, BF, Hubálek, F, Kjeldsen, T, et al.. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care 2021;9:2301. https://doi.org/10.1136/bmjdrc-2021-002301.Suche in Google Scholar PubMed PubMed Central

5. Mahapatra, MK, Karuppasamy, M, Sahoo, BM. Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. Rev Endocr Metab Disord 2022;23:521. https://doi.org/10.1007/s11154-021-09699-1.Suche in Google Scholar PubMed PubMed Central

6. Plum-Mörschel, L, Andersen, LR, Hansen, S, Hövelmann, U, Krawietz, P, Kristensen, NR, et al.. Pharmacokinetic and pharmacodynamic characteristics of insulin icodec after subcutaneous administration in the thigh, abdomen or upper arm in individuals with type 2 diabetes mellitus. Clin Drug Invest 2023;43:119–27. https://doi.org/10.1007/s40261-022-01243-6.Suche in Google Scholar PubMed PubMed Central

7. Kjeldsen, TB, Hubálek, F, Hjørringgaard, CU, Tagmose, TM, Nishimura, E, Stidsen, CE, et al.. Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans. J Med Chem 2021;64;8942–50. https://doi.org/10.1021/acs.jmedchem.1c00257.Suche in Google Scholar PubMed

8. Bajaj, HS, Bergenstal, RM, Christoffersen, A, Davies, MJ, Gowda, A, Isendahl, J, et al.. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care 2021;44:1586–94. https://doi.org/10.2337/dc20-2877.Suche in Google Scholar PubMed PubMed Central

9. Lingvay, I, Buse, JB, Franek, E, Hansen, MV, Koefoed, MM, Mathieu, C, et al.. A randomized, open-label comparison of once-weekly insulin icodec titration strategies versus once-daily insulin glargine U100. Diabetes Care 2021;44:1595–603. https://doi.org/10.2337/dc20-2878.Suche in Google Scholar PubMed PubMed Central

10. Rosenstock, J, Bajaj, HS, Janež, A, Silver, R, Begtrup, K, Hansen, MV, et al.. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med 2020;383:2107–16. https://doi.org/10.1056/nejmoa2022474.Suche in Google Scholar PubMed

11. Zerihun, K, Mhanna, M, Ayesh, H, Ghazaleh, S, Khader, Y, Beran, A, et al.. Efficacy and safety of insulin icodec versus glargine U100: a meta-analysis of randomized controlled trials. Transl Univ Toledo J Med Sci 2023;30:e480–3. https://doi.org/10.46570/utjms.vol11-2023-730.Suche in Google Scholar

12. Hartman, I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res 2008;6:54. https://doi.org/10.3121/cmr.2008.793.Suche in Google Scholar PubMed PubMed Central

13. He, X, Chen, L, Wang, K, Wu, H, Wu, J. Insulin adherence and persistence among Chinese patients with type 2 diabetes: a retrospective database analysis. Patient Prefer Adherence 2017;11:237. https://doi.org/10.2147/ppa.s123389.Suche in Google Scholar

14. Cameron, CG, Bennett Bpharm, HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009;180:400. https://doi.org/10.1503/cmaj.081180.Suche in Google Scholar PubMed PubMed Central

15. pakdaman, M, Akbari, R, Dehghan, H, Asgharzadeh, A, Namayandeh, M. The cost-effectiveness of insulin analogs and regular insulin for diabetes control: a case study in Iran. Int J Health Care Qual Assur 2020;33:323–31. https://doi.org/10.1108/ijhcqa-02-2019-0042.Suche in Google Scholar PubMed

16. Cazarim, Mde S, Rodrigues, JPV, da Cruz-Cazarim, ELC, Ayres, LR, Pereira, LRL. Cost-effectiveness of insulin analogs from the perspective of the Brazilian public health system. Braz J Pharma Sci 2017;53:e00178. https://doi.org/10.1590/s2175-97902017000300178.Suche in Google Scholar

17. Shi, A, Xie, P, Nielsen, LL, Skjøth, TV, He, X, Haugaard, SP. Pharmacokinetics, safety and tolerability of once-weekly subcutaneous semaglutide in healthy Chinese subjects: a double-blind, phase 1, randomized controlled trial. Adv Ther 2021;38:550–61. https://doi.org/10.1007/s12325-020-01548-y.Suche in Google Scholar PubMed PubMed Central

18. Ikushima, I, Jensen, L, Flint, A, Nishida, T, Zacho, J, Irie, S. A randomized trial investigating the pharmacokinetics, pharmacodynamics, and safety of subcutaneous semaglutide once-weekly in healthy male Japanese and caucasian subjects. Adv Ther 2018;35:531–44. https://doi.org/10.1007/s12325-018-0677-1.Suche in Google Scholar PubMed PubMed Central

19. Shaman, AM, Bain, SC, Bakris, GL, Buse, JB, Idorn, T, Mahaffey, KW, et al.. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 2022;145:575–85. https://doi.org/10.1161/circulationaha.121.055459.Suche in Google Scholar

20. Heise, T, Mari, A, DeVries, JH, Urva, S, Li, J, Pratt, EJ, et al.. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol 2022;10:418–29. https://doi.org/10.1016/s2213-8587(22)00085-7.Suche in Google Scholar PubMed

21. Zaazouee, MS, Hamdallah, A, Helmy, SK, Hasabo, EA, Sayed, AK, Gbreel, MI, et al.. Semaglutide for the treatment of type 2 diabetes mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes. Diabetes Metabol Syndr 2022;16:102511. https://doi.org/10.1016/j.dsx.2022.102511.Suche in Google Scholar PubMed

22. Verma, S, Al-Omran, M, Leiter, LA, Mazer, CD, Rasmussen, S, Saevereid, HA, et al.. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes Obes Metabol 2022;24:1288–99. https://doi.org/10.1111/dom.14700.Suche in Google Scholar PubMed PubMed Central

23. Liu, Y, Luo, X. New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation. Front Med 2022;16:17–24. https://doi.org/10.1007/s11684-021-0873-2.Suche in Google Scholar PubMed PubMed Central

24. Rodbard, HW, Lingvay, I, Reed, J, De La Rosa, R, Rose, L, Sugimoto, D, et al.. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab 2018;103:2291–301. https://doi.org/10.1210/jc.2018-00070.Suche in Google Scholar PubMed PubMed Central

25. Uzoigwe, C, Liang, Y, Whitmire, S, Paprocki, Y. Semaglutide once-weekly persistence and adherence versus other GLP-1 RAs in patients with type 2 diabetes in a US real-world setting. Diabetes Ther 2021;12:1475–89. https://doi.org/10.1007/s13300-021-01053-7.Suche in Google Scholar PubMed PubMed Central

26. Tofé, S, Argüelles, I, Mena, E, Serra, G, Codina, M, Urgelés, JR, et al.. An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain. Endocrine Metabol Sci 2021;2:100082. https://doi.org/10.1016/j.endmts.2021.100082.Suche in Google Scholar

27. Kim, N, Wang, J, Burudpakdee, C, Song, Y, Ramasamy, A, Xie, Y, et al.. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. J Manag Care Spec Pharm 2022;28:740–52. https://doi.org/10.18553/jmcp.2022.28.7.740.Suche in Google Scholar PubMed PubMed Central

28. Hu, Y, Zheng, SL, Ye, XL, Shi, JN, Zheng, XW, Pan, HS, et al.. Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting. Ann Transl Med 2022;10:152. https://doi.org/10.21037/atm-22-200.Suche in Google Scholar PubMed PubMed Central

29. Yang, W, Dong, X, Li, Q, Cheng, Z, Yuan, G, Liu, M, et al.. Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: the LixiLan-O-AP randomized controlled trial. Diabetes Obes Metabol 2022;24:1522–33. https://doi.org/10.1111/dom.14722.Suche in Google Scholar PubMed

30. Davies, MJ, Rosenstock, J, Ali, A, Russell-Jones, D, Souhami, E, Palmer, K, et al.. Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: post hoc analysis of the LixiLan-O randomized trial. Diabetes Obes Metabol 2022;24:34–41. https://doi.org/10.1111/dom.14543.Suche in Google Scholar PubMed PubMed Central

31. Yuan, X, Guo, X, Zhang, J, Dong, X, Lu, Y, Pang, W, et al.. Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: results from the LixiLan-L-CN randomized controlled trial. Diabetes Obes Metabol 2022;24:2182–91. https://doi.org/10.1111/dom.14803.Suche in Google Scholar PubMed PubMed Central

32. McCrimmon, RJ, Al, SS, Emral, R, Mohan, V, Sauque-Reyna, L, Trescolí, C, et al.. Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: design and baseline characteristics of the SoliMix randomized controlled trial. Diabetes Obes Metabol 2021;23:1221–31. https://doi.org/10.1111/dom.14354.Suche in Google Scholar PubMed

33. Ferrannini, E, Niemoeller, E, Dex, T, Servera, S, Mari, A. Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes. Diabetes Obes Metabol 2022;24:1159–65. https://doi.org/10.1111/dom.14688.Suche in Google Scholar PubMed PubMed Central

34. Gough, SCL, Bode, B, Woo, V, Rodbard, HW, Linjawi, S, Poulsen, P, et al.. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2014;2:885–93. https://doi.org/10.1016/s2213-8587(14)70174-3.Suche in Google Scholar PubMed

35. Billings, LK, Doshi, A, Gouet, D, Oviedo, A, Rodbard, HW, Tentolouris, N, et al.. Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial. Diabetes Care 2018;41:1009–16. https://doi.org/10.2337/dc17-1114.Suche in Google Scholar PubMed

36. Miller, E, Doshi, A, Grøn, R, Jódar, E, Őrsy, P, Ranthe, MF, et al.. IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy. Diabetes Obes Metabol 2019;21:2643–50. https://doi.org/10.1111/dom.13851.Suche in Google Scholar PubMed PubMed Central

37. Kawaguchi, Y, Miyamoto, S, Hajika, Y, Ashida, N, Hirota, T, Masumoto, K, et al.. Efficacy of IDegLira versus IDegAsp therapy in patients with type 2 diabetes: a randomized crossover study by isCGM. Adv Ther 2022;39:2688–700. https://doi.org/10.1007/s12325-022-02138-w.Suche in Google Scholar PubMed PubMed Central

38. Holst, JJ, Buse, JB, Rodbard, HW, Linjawi, S, Woo, VC, Boesgaard, TW, et al.. IDegLira improves both fasting and postprandial glucose control as demonstrated using continuous glucose monitoring and a standardized meal test. J Diabetes Sci Technol 2015;10:389–97. https://doi.org/10.1177/1932296815610124.Suche in Google Scholar PubMed PubMed Central

39. A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to weekly insulin icodec - full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05352815?term=IcoSema&draw=2&rank=1 [cited 2023 Jun 17].Suche in Google Scholar

40. A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to weekly semaglutide (COMBINE 2) - full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05259033?term=IcoSema&draw=2&rank=2 [cited 2023 Jun 17].Suche in Google Scholar

41. A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a combination of insulin icodec and semaglutide, controls blood sugar level in people with type 2 diabetes compared to insulin glargine taken daily with insulin aspart (COMBINE 3) - full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05013229?term=IcoSema&draw=2&rank=3 [cited 2023 Jun 17].Suche in Google Scholar

42. News details. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=167008. [cited 2024 May 22].Suche in Google Scholar

43. A research study to look at how insulin icodec and semaglutide work in the body of people from China with type 2 diabetes when given alone or together - full text view - ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05435677?term=IcoSema&draw=2&rank=4. [cited 2023 Jun 17].Suche in Google Scholar
Received: 2024-04-15
Accepted: 2024-05-25
Published Online: 2024-06-11

© 2024 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorials
  3. Targeting Rho GTPase regulators in cancer: are we hitting the mark?
  4. The pitfalls of linear regression in physiological research
  5. Reviews
  6. Lipid profile and mortality in patients with pulmonary thromboembolism; a systematic review and meta-analysis
  7. IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective
  8. Deucravacitinib: moderate-to-severe plaque psoriasis preventable?
  9. The key roles of thyroid hormone in mitochondrial regulation, at interface of human health and disease
  10. Uncovering the coronavirus outbreak: present understanding and future research paths
  11. Effects of thyroid hormones in skeletal muscle protein turnover
  12. Original Articles
  13. Effect of high-intensity interval training vs. moderate-intensity continuous training on cardiometabolic risk factors in overweight and obese individuals
  14. Alcohol promotes liver fibrosis in high fat diet induced diabetic rats
  15. Association between aerobic performance and physiological responses in Yo-Yo intermittent recovery test level 2, and the futsal-specific intermittent endurance test in trained futsal players
  16. Oral vs. injected: which vitamin D boost works best for low levels?
  17. Effects of an 8-week intervention of anulom vilom pranayama combined with heartfulness meditation on psychological stress, autonomic function, inflammatory biomarkers, and oxidative stress in healthcare workers during COVID-19 pandemic: a randomized controlled trial
  18. Ureteral access sheaths in RIRS: a retrospective, comparative, single-center study
https://doi.org/10.1515/jbcpp-2024-0058
Schlagwörter für diesen Artikel
insulin icodec; semaglutide; pharmacokinetics; efficacy; safety; cost effectiveness

Artikel in diesem Heft

  1. Frontmatter
  2. Editorials
  3. Targeting Rho GTPase regulators in cancer: are we hitting the mark?
  4. The pitfalls of linear regression in physiological research
  5. Reviews
  6. Lipid profile and mortality in patients with pulmonary thromboembolism; a systematic review and meta-analysis
  7. IcoSema: unveiling the future of diabetes management from a clinical pharmacology perspective
  8. Deucravacitinib: moderate-to-severe plaque psoriasis preventable?
  9. The key roles of thyroid hormone in mitochondrial regulation, at interface of human health and disease
  10. Uncovering the coronavirus outbreak: present understanding and future research paths
  11. Effects of thyroid hormones in skeletal muscle protein turnover
  12. Original Articles
  13. Effect of high-intensity interval training vs. moderate-intensity continuous training on cardiometabolic risk factors in overweight and obese individuals
  14. Alcohol promotes liver fibrosis in high fat diet induced diabetic rats
  15. Association between aerobic performance and physiological responses in Yo-Yo intermittent recovery test level 2, and the futsal-specific intermittent endurance test in trained futsal players
  16. Oral vs. injected: which vitamin D boost works best for low levels?
  17. Effects of an 8-week intervention of anulom vilom pranayama combined with heartfulness meditation on psychological stress, autonomic function, inflammatory biomarkers, and oxidative stress in healthcare workers during COVID-19 pandemic: a randomized controlled trial
  18. Ureteral access sheaths in RIRS: a retrospective, comparative, single-center study
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 4.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2024-0058/pdf
Button zum nach oben scrollen